Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 May 3;12(5):1318-20.
doi: 10.1080/21645515.2015.1121339. Epub 2016 Jan 25.

The shadow of inequitable conduct in the US patent application

Affiliations

The shadow of inequitable conduct in the US patent application

Bao-Chi Chang et al. Hum Vaccin Immunother. .

Abstract

Inequitable conduct regarding any single claim can render the entire patent unenforceable and further damage other related patents and applications in the assignee's patent portfolio. The adverse impact of inequitable conduct significantly became a litigation strategy. The US Federal Circuit (CAFC) observed that inequitable conduct as a patent litigation strategy had become a plague and thus tightened the standard for finding inequitable conduct in a case with full court judges. However, under the shadow of previous adverse impact of inequitable conduct, patent applicants may still submit many marginal related references. This study demonstrates that an applicant even prepared an information disclosure statement (IDS) as many as 50 pages. Actually, under the new standard, inequitable conduct would not further produce significant impact in the US patent system. Thus, a patent applicant need not submit marginal references but should distinguish the prior art from the current application, especially for those listed in the IDS, to avoid the novelty rejection.

Keywords: inequitable conduct; information disclosure statement; intent; materiality; patent portfolio.

PubMed Disclaimer

Similar articles

References

    1. Wang S-J. The obviousness rejection as a barrier to biotech patent prosecution. Nat Biotech 2009; 27:1125-1126; PMID:20010590; http://dx.doi.org/10.1038/nbt1209-1125 - DOI - PubMed
    1. Wang S-J. The obviousness rejection as a barrier to vaccine patent prosecution. Human Vaccines 2011; 7:475-477. - PubMed
    1. Wang S-J. The written description rejection as a barrier to biotech patent prosecution. Human Vaccines 2011; 7:569-573; PMID:21552000; http://dx.doi.org/10.4161/hv.7.5.14358 - DOI - PubMed
    1. Durham A. Patent Law Essentials. Westport, CT: Quorum Books, 1999.
    1. Kingsdown Med. Consultants, Ltd. v. Hollister Inc. , United States Court of Appeals for the Federal Circuit. 863 F.2d 867, 1988.

MeSH terms

LinkOut - more resources